Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)

TITLE I INTRODUCTORY PROVISIONS

CHAPTER 1

	Subject matter and definitions
Article 1	This Regulation lays down rules concerning the development of medicinal
Article 2	In addition to the definitions laid down in Article 1 of
	CHAPTER 2
	Paediatric committee
Article 3 Article 4	(1) By 26 July 2007, a Paediatric Committee shall be(1) The Paediatric Committee shall be composed of the following
Article 5	(1) When preparing its opinions, the Paediatric Committee shall
Article 6	use (1) The tasks of the Paediatric Committee shall include the

TITLE II

MARKETING AUTHORISATION REQUIREMENTS

CHAPTER 1

General authorisation requirements

Article 7	(1) An application for marketing authorisation under Article 6 of
	Directive
Article 8	In the case of authorised medicinal products which are
	protected
Article 9	Articles 7 and 8 shall not apply to products authorised
Article 10	In consultation with the Member States, the Agency and other

CHAPTER 2

Waivers

Article 11 (1) Production of the information referred to in point (a)...

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

Article 12 Article 13 Article 14	The Paediatric Committee may of its own motion adopt an (1) The applicant may, on the grounds set out in (1) The Agency shall maintain a list of all waivers
	CHAPTER 3
	Paediatric investigation plan
	Section 1
	Requests for agreement
Article 15 Article 16 Article 17 Article 18 Article 19	 Where the intention is to apply for a marketing In the case of the applications for marketing authorisation Following receipt of a proposed paediatric investigation plan which As soon as the Paediatric Committee adopts an opinion, whether having considered a paediatric investigation plan, the Paediatric Committee
	Section 2
	Deferrals
Article 20 Article 21	(1) At the same time as the paediatric investigation plan(1) At the same time as the Paediatric Committee adopts
	Section 3
	Modification of a paediatric investigation plan
Article 22	If, following the decision agreeing the paediatric investigation plan, the
	Section 4
	Compliance with the paediatric investigation plan
Article 23	(1) The competent authority responsible for granting marketing authorisation shall
Article 24	If, when conducting the scientific assessment of a valid application
	CHAPTER 4
	Procedure
Article 25	(1) Within ten days of its receipt, the Agency shall

Document Generated: 2023-08-27

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

CHAPTER 5

Miscellaneous provisions

Article 26 Any legal or natural person developing a medicinal product intended...

TITLE III

MARKETING AUTHORISATION PROCEDURES

Article 27 Save where otherwise provided in this Title, marketing authorisation procedures...

CHAPTER 1

Marketing authorisation procedures for applications falling within the scope of Articles 7 and 8

- Article 28 (1) Applications may be submitted in accordance with the procedure...
- Article 29 In the case of medicinal products authorised under Directive 2001/83/EC,...

CHAPTER 2

Paediatric use marketing authorisation

Article 30 (1) Submission of an application for a paediatric use marketing... Article 31 Without prejudice to Article 3(2) of Regulation (EC) No 726/2004, an application...

CHAPTER 3

Identification

Article 32 (1) Where a medicinal product is granted a marketing authorisation...

TITLE IV

POST-AUTHORISATION REQUIREMENTS

Article 33 Where medicinal products are authorised for a paediatric indication following... Article 34 (1) In the following cases, the applicant shall detail the... Article 35 If a medicinal product is authorised for a paediatric indication...

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

TITLE V

REWARDS AND INCENTIVES

 Where an application under Article 7 or 8 includes Where an application for a marketing authorisation is submitted in Where a paediatric use marketing authorisation is granted in In addition to the rewards and incentives provided for Funds for research into medicinal products for the paediatric
TITLE VI
COMMUNICATION AND COORDINATION
(1) The European database created by Article 11 of Directive 2001/20/EC
Member States shall collect available data on all existing uses
(1) On the basis of the information referred to in
(1) The Agency shall, with the scientific support of the
(1) By 26 January 2008, any paediatric studies already completed,
(1) Any other marketing authorisation holder-sponsored studies which involve the

TITLE VII

GENERAL AND FINAL PROVISIONS

CHAPTER 1

General provisions

Section 1

Fees, community funding, penalties and reports

Article 47	(1) Where an application for a paediatric use marketing
	authorisation
Article 48	The Community contribution provided for in Article 67 of
	Regulation (EC)
Article 49	(1) Without prejudice to the Protocol on the Privileges and
Article 50	(1) On the basis of a report from the Agency,

Section 2

Standing committee

Article 51 (1) The Commission shall be assisted by the Standing Committee...

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

CHAPTER 2

Amendments

Article 52	Regulation (EEC) No 1768/92 is hereby amended as follows: in Article 1,
Article 53	In Article 11 of Directive 2001/20/EC, the following paragraph shall be
Article 54	In Article 6 of Directive 2001/83/EC, the first subparagraph of paragraph
Article 55	Regulation (EC) No 726/2004 is hereby amended as follows: Article 56(1) shall
	CHAPTER 3
	Final provisions
Article 56 Article 57	The requirement laid down in Article 7(1) shall not apply to (1) This Regulation shall enter into force on the thirtieth Signature

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (1) OJ C 267, 27.10.2005, p. 1.
- (2) Opinion of the European Parliament of 7 September 2005 (OJ C 193 E, 17.8.2006, p. 225), Council Common Position of 10 March 2006 (OJ C 132 E, 7.6.2006, p. 1) and Position of the European Parliament of 1 June 2006 (not yet published in the Official Journal). Council Decision of 23 October 2006.
- (3) OJ L 121, 1.5.2001, p. 34.
- (4) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).
- (5) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).
- (6) OJ L 182, 2.7.1992, p. 1. Regulation as last amended by the 2003 Act of Accession.
- (7) OJ L 18, 22.1.2000, p. 1.
- (8) OJ L 184, 17.7.1999, p. 23. Decision as amended by Decision 2006/512/EC (OJ L 200, 22.7.2006, p. 11).

Changes to legislation:

There are outstanding changes not yet made to Regulation (EC) No 1901/2006 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

View outstanding changes

Changes and effects yet to be applied to:

- Regulation revoked in part by S.I. 2019/775 Sch. 9 para. 1(1)